Drug Profile
Ethinylestradiol/levonorgestrel (ascending/constant dose) - Teva Pharmaceutical Industries
Alternative Names: DR 1031; DR-0131; Levonorgestrel/ethinyl estradiol and ethinyl estradiol; Levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets; QuartetteLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pregnancy
Most Recent Events
- 06 Feb 2019 Chemical structure information added
- 10 Feb 2014 Teva has patent protection for ethinylestradiol/levonorgestrel (ascending/constant dose) in USA
- 24 Sep 2013 Launched for Contraception/Pregnancy (Prevention) in USA (PO) - First global launch